Drugs / recMAGE-A3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01425749 | Jun 2011 → Jul 2013 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01380145 | Sep 2011 → Jul 2014 | plasma cell myeloma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01266603 | Feb 2011 → Nov 2018 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01435356 Comparator | Aug 2011 → Apr 2017 | bladder transitional cell carcinoma | European Association of Urology Research Foundation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recMAGE-A3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01425749 ↗ |
| Known as | recombinant MAGE-A3 protein | “The immunostimulant AS15 has been administered with the recombinant MAGE-A3 protein (recMAGE-A3) i.m. but not i.d. or s.c.” PMID 26581199 ↗ Nov 2015 |
| Action | Deplete | “training your body to recognize it and to destroy the cells that have this protein” NCT01266603 ↗ |
| Modality | Protein / enzyme biologic | “This is done by injecting a protein (the MAGE-A3 protein) that is found in the tumor” NCT01266603 ↗ |
| Route | Other | “by intermuscular injection” NCT01266603 ↗ |